Malaysia
Tuberculosis profile
Population  2013 30 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.7 (0.95–2.7) 5.8 (3.2–9.2)
Mortality (HIV+TB only) 0.44 (0.26–0.67) 1.5 (0.89–2.3)
Prevalence  (includes HIV+TB) 39 (18–67) 131 (62–225)
Incidence  (includes HIV+TB) 29 (26–33) 99 (86–110)
Incidence (HIV+TB only) 2 (1.8–2.2) 6.6 (5.9–7.5)
Case detection, all forms (%) 79 (71–92)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.1 (0–0.6) 0 (0–17)
MDR-TB cases among notified pulmonary
TB cases
19 (0–120) 0 (0–280)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 13 641   676
Pulmonary, clinically diagnosed 5 640   307
Extrapulmonary 3 046   107
       
Total new and relapse 23 417    
Previously treated, excluding relapses 654    
Total cases notified 24 071    
Among 23 417 new and relapse cases:
644 (3%) cases aged under 15 years; male:female ratio: 1.8
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 3 187 (23%) 194 (11%) 13 198
Laboratory-confirmed RR-/MDR-TB cases     277
Patients started on MDR-TB treatment     49
TB/HIV 2013 Number (%)
TB patients with known HIV status 20 635 (86)
HIV-positive TB patients 1 510 (7)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 60 (4)
HIV-positive TB patients on antiretroviral therapy (ART) 407 (27)
HIV-positive people screened for TB 7 017  
HIV-positive people provided with IPT 1 220  
Treatment success rate (%)
New and relapse cases registered in 2012 78
Previously treated cases, excluding relapse, registered in 2012 57
HIV-positive TB cases, all types, registered in 2012 46
RR-/MDR-TB cases started on second-line treatment in 2011 28
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 2.6
Culture (per 5 million population) 5.9
Drug susceptibility testing (per 5 million population) 0.3
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 16
% Funded domestically 100%
% Funded internationally 0%
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-05-25 Data: www.who.int/tb/data